Company News

ALPHARETTA, GA / ACCESSWIRE / October 19, 2021 / RushNet, Inc (OTC PINK:RSHN), (“the Company”) is pleased to announce that it’s subsidiary heliosDX has been invited to present at the Emerging Growth Conference on Wednesday October 27, 2021.

heliosDX invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.

The next Emerging Growth Conference is presenting on Wednesday October 27, 2021. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company’s Chief Operations Officer, Yann Gerville-Réache in real time.

Mr. Gerville-Réache will perform a presentation and may subsequently open the floor for questions. At that time, Mr. Gerville-Réache will be joined by the Chief Executive Officer, Ashley Sweat. Please ask your questions during the event and Mr. Gerville-Réache and Mr. Sweat will do their best to get through as many of them as possible.

heliosDX will be presenting at 10:30 AM Eastern time for 30 minutes.

Please register here (https://goto.webcasts.com/starthere.jsp?ei=1487783&tp_key=a4da498b3a&sti=rshn) to ensure you are able to attend the conference and receive any updates that are released.

If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and we will also release a link to that after the event.

About the Emerging Growth Conference

The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services, and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

About HeliosDx:

heliosDX is a National Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. We are contracted in 44 of the lower 48 states and looking to expand our reach and capabilities. We intend to always stay ahead of the curve by continually investing in our infrastructure with the most efficient scientific proven instruments and latest cutting-edge software for patient and physician satisfaction. In management’s opinion, following such best practices are intended to allow heliosDX to provide physicians fast and accurate reporting, meeting and exceeding industry benchmarks. It is our goal to excel in patient and client care through physician designed panels that aid in testing compliance and reporting education.

Contact:

Ashley Sweat
asweat@heliosdx.com
www.heliosdx.com
Twitter Handle: @dx_helios

Safe Harbor Notice

Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions that statements, and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –

On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment, or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be averse to the pecuniary interests of the Company and of its shareholders.

SOURCE: RushNet, Inc

View source version on accesswire.com:
https://www.accesswire.com/668740/heliosDX-to-Present-at-the-Emerging-Growth-Conference-onWednesday-October-27-2021-Invites-Institutional-and-Individual-Investors

Leave a Reply

Your email address will not be published. Required fields are marked *

Post comment